Stay updated with breaking news from Andrea Chicca. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This article spotlights the driving forces behind Basel’s snowballing reputation, and notes some of the success stories arising from this innovative biotech powerhouse.
/PRNewswire/ -- Synendos Therapeutics (Synendos), a biopharmaceutical company focused on restoring the natural functioning of the endocannabinoid system to...
/PRNewswire/ -- Synendos Therapeutics (Synendos), a biopharmaceutical company focused on restoring the natural functioning of the endocannabinoid system to...
Synendos Therapeutics Expands Series A to CHF 24 million with new investment - Ysios Capital joins existing syndicate co-led by Kurma Partners and Sunstone Life Science Ventures - This investment brings total Series A financing to CHF 24 million to complete pre-clinical development and progress lead candidate through proof-of-concept clinical studies - In addition, Synendos Therapeutics secures prestigious Eurostars grant (EU funding scheme) to expand proof-of-concept preclinical studies for PTSD - Professor Jutta Heim appointed as Chair to the Board News provided by Share this article Share ...